TearLab Corporation to Release Q3-09 Financial Results on November 12 --
Conference Call to Follow
SAN DIEGO, Nov. 4, 2009 (GLOBE NEWSWIRE) -- OccuLogix, Inc. dba TearLab
Corporation (Nasdaq:TEAR)(TSX:TLB) expects to announce its third quarter 2009
financial results after the market closes on Thursday, November 12, 2009.
OccuLogix is pleased to invite all interested parties to participate in a
conference call during which the financial results will be discussed. The call
will be held on November 12, at 4:30p.m. Eastern Time at 800-311-0799 (within
the United States and Canada).
Date: November 12, 2009
Time: 4:30 PM ET
Listen via Internet: http://www.tearlab.com/us/shareholder.htm/
Schedule this webcast into MS-Outlook calendar (click open when prompted):
http://apps.shareholder.com/PNWOutlook/t.aspx?m=39689&k=8C537C6C
Toll-free: 1-800-311-0799
International: 1-719-955-9039
The call will be broadcast live at
http://investor.shareholder.com/media/eventdetail.cfm?eventid=74622&CompanyID=TE
R&e=1&mediaKey=EDDE19B7CCF05968104464D9ECD2AD4C and archived on the company's
web-site at www.tearlab.com under the "webcasts" link in the investor Relations
section.
About OccuLogix, Inc. dba TearLab Corporation
OccuLogix dba TearLab Corporation (www.tearlab.com) develops and commercializes
lab-on-a-chip technologies that enable eye care practitioners to improve
standard of care by quantitatively testing for disease markers in tears at the
point-of-care. Headquartered in San Diego, CA, TearLab Corporation's common
shares trade on the NASDAQ Capital Market under the symbol 'TEAR' and on the
Toronto Stock Exchange under the symbol 'TLB'. TearLab received the CE Mark for
its TearLab(TM) Osmolarity System in 2008 and FDA Clearance in 2009. TearLab is
currently marketed globally in more than 17 countries including the U.S.
Forward-Looking Statements
This press release may contain forward-looking statements, including statements
regarding the growth of the market for dry eye disease products, the impact of
our product on the management of affected patients, and our intention to seek
CLIA Waiver. These statements relate to future events and are subject to risks,
uncertainties and assumptions about the Company. These statements are only
predictions based on our current expectations and projections about future
events. You should not place undue reliance on these statements. Actual events
or results may differ materially. Many factors may cause our actual results to
differ materially from any forward-looking statement, including the factors
detailed in our filings with the Securities and Exchange Commission and Canadian
securities regulatory authorities, including but not limited to our Forms 10-K
and 10-Q. We do not undertake to update any forward-looking statements.
-0-
CONTACT: TearLab Corporation
Tracy Puckett, V.P. Marketing
678-566-3829
tpuckett@tearlab.com
William Dumencu, CFO & Treasurer
905-636-0128
bdumencu@tearlab.com
